E
Emendo Biotherapeutics
Develops next-generation gene editing using synthetic biology to address untreatable diseases
About Emendo Biotherapeutics
Emendo Biotherapeutics is a biotechnology startup that is revolutionizing the field of gene editing. The company utilizes a novel approach to the CRISPR-Cas9 system, a technology that allows scientists to edit genes within organisms. Emendo Biotherapeutics' unique approach involves understanding each genetic disease individually and then devising an optimal editing strategy. This approach is a departure from the traditional use of CRISPR, which has been limited by its inability to fully address complex genetic diseases.
Read full description
The company serves clients in the healthcare and medical research sectors, providing them with innovative solutions for genetic diseases. Emendo Biotherapeutics operates in the biotechnology market, a sector that is expected to grow significantly due to the increasing prevalence of diseases that require genetic intervention.
Emendo Biotherapeutics' business model revolves around the development and commercialization of its unique CRISPR solutions. The company makes money by licensing its technology to healthcare and research institutions. Additionally, it also generates revenue through partnerships with pharmaceutical companies that are interested in using its technology for drug development.
In summary, Emendo Biotherapeutics is a pioneering biotech startup that is pushing the boundaries of gene editing. Its unique approach to CRISPR-Cas9 technology has the potential to make a significant impact on the treatment of genetic diseases.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- New York City, United States
- Employees
- 40
- Open positions
- None listed
- Dealroom signal
- 64.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Synthetic Biology, Crispr, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Apr 2023 | $10M | $305M | AnGes | — |
| LATE VCOther financing | Jun 2022 | $30M | $305M | AnGes | — |
Growth signals
Latest recorded traffic for Emendo Biotherapeutics is 960 monthly website visits, down 4% over the last three months. Emendo Biotherapeutics's team grew 2.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
OrbiMed
Takeda
AnGes
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Emendo Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Emendo Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.